Login to Your Account



Plexxikon Drug Quickly Moves From Phase I to Pivotal Trials

By Catherine Hollingsworth


Wednesday, September 30, 2009
In relatively short order, Plexxikon Inc. has moved its melanoma product from a Phase I study to pivotal trials, the first of which has begun enrolling patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription